This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Venture-Backed Life Science Companies Hit 7 Year Highs In Large Acquisitions

SANTA CLARA, Calif., July 19, 2012 /PRNewswire/ --  Silicon Valley Bank, financial partner to technology and life science companies and their investors worldwide, released a study today that examines the merger and acquisition behavior of private, venture capital-backed biotech and medical device companies.

(Photo:  http://photos.prnewswire.com/prnh/20120719/SF42867)

(Logo:  http://photos.prnewswire.com/prnh/20100106/SF32918LOGO)

Based on an analysis of private merger or acquisition transactions of US venture capital-backed companies since 2005, Silicon Valley Bank found a rebound in "Big Exits" among life science companies. Big Exits were defined as acquisitions where the upfront payment totaled in excess of $50 million for device companies and $75 million for biotech companies:

  • 35 Big Exits in 2011 -- 7 year high
  • $12.5 billion invested in life science -- 7 year high
  • Increased upfront deal values in biotech
  • Indications receiving the largest investments since 2005:
    • BIOTECH:   Oncology, CNS, Anti-Infectives
    • DEVICE:   Diagnostics, Orthopedics, Cardiovascular
  • Sectors with the highest multiples, versus dollars deployed since 2005:
    • BIOTECH:   Respiratory, Cardiovascular, Oncology
    • DEVICE:   Surgical, Vascular, Tools

The full report, "Continued Rebound: Trends in Life Science M&A," is available here.  A tandem report, examining the current and emerging trends in life science investments, "First Mover Advantage: The Case for Investing in Life Science," is also available.

"Our data shows positive momentum in exits in the life science industry," said Jonathan Norris, Managing Director with SVB Capital's Venture Capital Relationship Management team and author of the report. "In 2011 we saw the most VC-backed big exits, generating the largest amount of liquidity in biotech and device, since we started tracking this data in 2005. While this does not correct the poor overall returns for the last decade, these dynamics position life science as an attractive investment opportunity now and in the future."

Silicon Valley Bank works with 50 percent of life science-focused VC firms and life science companies nationwide, specializing in companies in biotech and medical device fields.

About Silicon Valley Bank Silicon Valley Bank is the premier bank for technology, life science, venture capital, private equity and premium wine businesses. SVB provides industry knowledge and connections, financing, treasury management, corporate investment and international banking services to its clients worldwide through 27 U.S. offices and seven international operations.  (Nasdaq: SIVB) www.svb.com .

Silicon Valley Bank is the California bank subsidiary and the commercial banking operation of SVB Financial Group. Banking services are provided by Silicon Valley Bank, a member of the FDIC and the Federal Reserve System. SVB Financial Group is also a member of the Federal Reserve System.

SOURCE Silicon Valley Bank

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,142.46 +45.56 0.25%
S&P 500 2,101.35 +2.82 0.13%
NASDAQ 4,984.3960 +17.2550 0.35%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs